Duke University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Duke University sits in the top decile of US sponsors by registered trial count (#9 of 15,742 sponsors by registered trial count).
Duke University: 1,725 sponsored US clinical trials, 187 recruiting.
Duke University sponsors 1,725 registered US clinical trials on ClinicalTrials.gov, 187 of them currently recruiting, and 1,244 completed. 175 of these trials are in Phase 3-4 (later-stage) and 311 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 15 trials.
Top-decile sponsor footprint
Duke University ranks in the top decile of sponsors by registered trial count (#9 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,244 of 1,444 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,725 total, page 1 of 35
Behavioral Pain Intervention for Older Cancer Patients
NCT07300995
Flex Appeal: Evaluating the Efficacy of Anesthetic Techniques for Manipulation of Knees Under Anesthesia
NCT07348614
Stress and Menstrual Health
NCT07566260
CVFs in SIH: EID vs. PCD CTM
NCT07582744
Project DEDUCE: Digital Envirotyping to Develop Understanding of Cigarette Smoking and the Environment
NCT07089901
SickleFit Exercise and Nutrition Study
NCT07442851
The Impact of Music Intervention on Sleep
NCT06088810
Virtual Agent Feasibility in Oncology Patients (NTT Data)
NCT06682013
Siemens Biomarker Multi-modality
NCT07495332
Advancing Pediatric Retinal Imaging With Auto-aligned OCT
NCT06841575
Assessment of Topical Minoxidil on Intraoperative Flap Perfusion and Cutaneous Flap Viability in Breast Recon
NCT07264790
IL-17 Blockade to Decrease irAEs (REPLAY)
NCT07237594
Validation of a Platelet Proteomic Assay for Diagnosing and Monitoring Prostate Cancer
NCT07144228
Automated Applanation Tonometry - Updated
NCT07298356
Family Building Decision Support for Female Adolescent and Young Adult Cancer Survivors
NCT07471685
PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysplasia
NCT07101640
Optimizing Recovery in Trauma Patients by Integrating Enhanced Nutrition Delivery
NCT06521086
Using PrEP, Doing It for Ourselves
NCT06638892
Intestinal Microbiome Transplant in ALS
NCT07017946
Improving Outcomes in Early Menopause After Cancer
NCT06982677
Improving Hypertension Control in Rheumatoid Arthritis
NCT05760898
Development of a Pain Control Options Menu for IUD Insertion
NCT07278804
Allopregnanolone (Zuranolone) in Post-stroke Depression
NCT06759558
Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP
NCT07218211
Weight Management After Cancer for Survivors in Rural Communities
NCT07426952
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis
NCT06654882
Mindfulness Intervention for Sleep Disturbance and Symptom Management in Hematologic Cancer Patients During and After Inpatient Treatment
NCT06532773
Yoga for Treatment of Overactive Bladder in Pediatric Patients
NCT05895045
Low Intensity Focused Ultrasound Stimulation in Stroke Patients - Parameter Optimization
NCT07220005
Sex Differences in Barriers and Participation in Physical Activity During and Following Cardiac Rehabilitation
NCT07214350
Virtual Reality Use for ICU Mobility
NCT07234201
Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab
NCT06816927
Photon-counting CT in Chest Imaging
NCT07031336
Cardiac point-of Care Ultrasound Training Pathway for Emergency Department Advanced Practice Providers
NCT07159269
HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT
NCT06731504
Pediatrics Mobile CT
NCT07166926
Neural Correlates and Behavioral Impact of Withdrawal-induced Hyperalgesia Among People Who Smoke With and Without Chronic Pain
NCT06983678
Timing of Physician Rounds for Antepartum Patients
NCT07215507
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)
NCT06906627
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)
NCT06906640
Characterizing the Microvascular Environment of Bladder Cancer With Super-Resolution Ultrasound Localization Microscopy
NCT06986304
Eat Well Heart Failure
NCT07101289
Safety of RSV Preventive Monoclonal Antibody
NCT07158814
Widefield Confocal Scanning Laser Ophthalmoscope Optimized for Pediatric and Neonatal Imaging
NCT06177639
Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy
NCT06972719
Comparative Efficacy of Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI)
NCT07089745
Repurposing Tilmanocept for Cardiac Sarcoidosis
NCT07159074
MAPS PrEP Van Study
NCT06908252
Improving Needs Among Older Adults
NCT06588556
Developing and Testing Drone-Delivered AEDs for Cardiac Arrests In Rural America
NCT06229418
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 136 |
| Phase 2 | 175 |
| Phase 3 | 41 |
| Phase 4 | 134 |
Therapeutic Areas
What is open in the Duke University pipeline
187 recruiting of 1,725 indexed (11% open); 1,244 completed (72%).
Phase mix: 175 late (III/IV) vs 311 early (I/II) (early-phase heavy).
Top condition: Obesity (15 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Duke University: open-pipeline peers nationwide
Peers matched on 1,725 registered trials and 11% open enrollment, not the therapeutic-area sidebar.
Duke University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,725 trials (± recruiting share)
- University of California, San Francisco · 1,713 trials · 16% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- VA Office of Research and Development · 1,668 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
Sponsors near 11% open enrollment (± trial volume)
- Carnegie Mellon University · 11% recruiting · 37 trials
- CAMC Health System · 11% recruiting · 28 trials
- UConn Health · 11% recruiting · 178 trials
- Hartford Hospital · 11% recruiting · 75 trials
Related
What to do with this Duke University page
1,725 registered trials is a research-attention snapshot, not an endorsement of Duke University or any single study.
- 187 of Duke University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition Duke University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Duke University pipeline card: 1,725 registered trials from official public datasets.Report a data error.